)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Sagimet Biosciences
Sagimet Biosciences (SGMT) investor relations material
Sagimet Biosciences Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary11 Feb, 2026
Company overview and strategy
Focuses on FASN inhibition to address MASH, acne, and certain solid tumors, with Denifanstat as the lead program.
Denifanstat is unique in directly inhibiting fat, inflammation, and fibrosis, unlike other fat-burning mechanisms in MASH.
Pipeline includes next-generation FASN inhibitors, with TVB-3567 advancing for acne.
Commercial strategy separates molecules for MASH and acne to optimize IP and market positioning.
Cash reserves of $125 million expected to fund operations through 2027, supporting key clinical milestones.
Clinical progress in MASH
Phase II data showed pronounced fibrosis reduction in F2/F3 and F3 MASH patients.
In a digitally diagnosed F4 subpopulation, 11 of 13 patients improved by one or two fibrosis stages.
Combination with resmetirom showed no safety signals and supports phase II initiation in F4/cirrhotic patients.
Phase II MASH study to start by end of 2024, with interim biomarker readout in early 2028 and 52-week data in late 2028.
Goal is to demonstrate fibrosis regression in F4 patients, leveraging additive effects of Denifanstat and resmetirom.
Acne program and market context
Denifanstat demonstrated ~20% reduction in lesion count and IGA improvement in phase II/III China studies.
NDA for Denifanstat in acne accepted by Chinese regulators, with approval expected late 2024 or early 2025.
52-week extension study confirmed strong safety and sustained efficacy, with most patients achieving IGA 0/1.
U.S. KOLs view Chinese data as reliable and compelling for moderate to severe acne.
Novel oral FASN inhibitor mechanism addresses unmet need as guidelines shift away from antibiotics.
MASH F4 interim data readout timeline?
TVB-3567 Phase 1 data confirming denifanstat similarity?
Cash runway coverage for MASH enrollment completion?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Sagimet Biosciences earnings date
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb, 2026
Sagimet Biosciences
Next Sagimet Biosciences earnings date
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Sagimet Biosciences Inc., previously known as 3-V Biosciences, Inc., is a clinical-stage biopharmaceutical company. It focuses on developing innovative therapeutics called fatty acid synthase (FASN) inhibitors. These inhibitors target diseases caused by the overproduction of the fatty acid, palmitate, including non-alcoholic steatohepatitis (NASH), acne, and various forms of cancer. Sagimet Biosciences' expertise in fatty acid synthase allows it to pioneer treatments for these diseases by targeting dysfunctional metabolic pathways. Its lead product candidate, denifanstat, is an oral, once-daily selective FASN inhibitor, currently being evaluated in clinical trials for patients with NASH. The company was incorporated in 2006 and is headquartered in San Mateo, California, USA. Its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage